|STUDY YIELDS PROMISING RESULTS
“For the first time, people are beginning to think about a cure” as a possibility, said Dr. John Zaia, who oversees research.
Gene therapy leads to new hope for AIDS cure
Scientists test HIV-resistant blood cells
NEW YORK — In a bold new approach ultimately aimed at trying to cure AIDS, scientists used genetic engineering in six patients to develop blood cells that are resistant to HIV, the virus that causes the disease.
It’s far too early to know if this scientific first will prove to be a cure, or even a new treatment. The research was only meant to show that, so far, it seems feasible and safe.
The concept was based on an astonishing case nearly four years ago in Berlin of an AIDS patient who seems to be cured after getting blood cells from a donor with natural immunity to HIV. Researchers are seeking a more practical way to achieve similar immunity using patients’ own blood cells.
The results were announced yesterday in Boston at the Conference on Retroviruses and Opportunistic Infections, which drew researchers and clinicians from around the world.
“For the first time, people are beginning to think about a cure’’ as a real possibility, said Dr. John Zaia, head of the government panel that oversees gene therapy experiments. Even if the new approach doesn’t get rid of HIV completely, it may repair patients’ immune systems enough that they can control the virus and not need AIDS medicines — “what is called a functional cure,’’ he said.
Carl Dieffenbach, AIDS chief at the National Institute of Allergy and Infectious Diseases, agreed. “We’re hopeful that this is sufficient to give the level of immune reconstitution similar to what was seen with the patient from Germany,’’ he said.
This is the first time researchers have permanently deleted a human gene and infused the altered cells back into patients. Other gene therapy attempts tried to add a gene or muffle the activity of one, and have not worked against HIV.
The virus can damage the immune system for years before people develop symptoms and are said to have AIDS — acquired immune deficiency syndrome. The virus targets special immune system soldiers called T-cells. It usually enters these cells through a protein receptor, or “docking station,’’ called CCR5.
Some people (about 1 percent of whites; fewer of minorities) lack both copies of the CCR5 gene and are naturally resistant to HIV. One such person donated blood stem cells in 2007 to an American man living in Berlin who had leukemia and HIV.
The cell transplant appears to have cured both problems, but finding such donors for everyone with HIV is impossible, and transplants are medically risky.
So scientists wondered: Could a patient’s own cells be used to knock out the CCR5 gene and create resistance to HIV?
A California biotechnology company,
Dr. Jacob Lalezari, director of Quest Clinical Research of San Francisco, led the first test of this with the company and colleagues at the University of California in San Francisco and Los Angeles.
He warned that it would be “way overstated’’ to suggest that the results so far are a possible cure.
In the study, six men with HIV had their blood filtered to remove a small percentage of their T-cells. The gene-snipping compound was added in the lab, and about one-fourth of the cells were successfully modified. The cells were mixed with growth factors to make them multiply and then infused back into the patients.
Three months later, five men had three times the number of modified cells expected. As much as 6 percent of their total T-cells appear to be the new type — resistant to HIV, Lalezari said.
It will take longer to determine safety, but several AIDS researchers said they were encouraged so far.
“It is a huge step’’ and a first for the field of genetics, said John Rossi, a researcher at City of Hope in Duarte, Calif., where he and Zaia plan another study to test Sangamo’s approach. “The idea is if you take away cells the virus can infect, you can cure the disease.’’
Tomorrow, Dr. Carl June, a gene therapy specialist at the University of Pennsylvania, will report partial results from a second study of 10 people testing Sangamo’s product.